Antimicrobial stewardship: A review

Infectious Diseases in Clinical Practice

Volumn 19, Issue 6, 2011, Pages 382-387

  Louie, Ted ^a,b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

antibiotic de escalation; antibiotic stewardship; antimicrobial stewardship

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFAZOLIN; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ECHINOCANDIN; IMIPENEM; LINEZOLID; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER SYSTEM; COST CONTROL; DEVICE INFECTION; DRUG CONTRAINDICATION; DRUG COST; DRUG PROGRAM; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; GRAM NEGATIVE BACTERIUM; HEALTH CARE QUALITY; HOSPITAL COST; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; KLEBSIELLA; KLEBSIELLA INFECTION; LENGTH OF STAY; MEDICAL INFORMATION SYSTEM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRESCRIPTION; PSEUDOMONAS; REIMBURSEMENT; REVIEW; TEAMWORK; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 80855130368     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e3182349ca5     Document Type: Review

References (68)

1. Owens RC Jr, Ambrose PG, Nightingale CH. Antibiotic Optimization: Concepts and Strategies in Clinical Practice. New York, NY: Marcel Dekker; 2005, v.
2. Cosgrove S. Driving Change: Why Antimicrobial Stewardship? Premeeting Session 1. No. 2 IDSA. Alexandria, VA: Society for Healthcare Epidemiology of America; 2010.
3. Shlaes DM, Gerding DN, John JF, et al. SHEA and IDSA joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25:584-599.
4. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-177. (Pubitemid 46084814)
5. Trivedi KK. Small Group Session of: Implementing Antimicrobial Stewardship Programs: A Workshop on Development, Maintenance and Measuring Success. Premeeting session 1. No. 2. IDSA. Alexandria, VA: Society for Healthcare Epidemiology of America; 2010.
6. Hoffman JM, Shah ND, Vermuelen LC. Projecting future drug expendituresV2007. Am J Health Syst Pharm. 2007;64:298-314.
7. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis. 1997;24:471-485. (Pubitemid 27096806)
8. MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005;41:435-440. (Pubitemid 41099634)
9. Muller AA, Mauny F, Bertin M, et al. Relationship between spread of MRSA and antimicrobial use in a French university hospital. Clin Infect Dis. 2003;36:971-978. (Pubitemid 36513280)
10. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with MRSA in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. Clin Infect Dis. 2005;41:159-166. (Pubitemid 40962495)
11. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000;36:145-158. (Pubitemid 30145652)
12. Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences. J Hosp Infect. 2007;65:204-211.
13. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-1171. (Pubitemid 32390110)
14. Souli M, Galani I, Antoniadou A, et al. An outbreak due to infection due to beta lactamase Klebsiella pneumoniae carbapenemase 2 producing K. pneumoniae in a Greek university hospital: Molecular characterization, epidemiology and outcomes. Clin Infect Dis. 2010;50:364-373.
15. Healthgrades I. Second Annual Patient Safety in American Hospitals Report-May 2005. Available at: Http://www.healthgrades.com/media/ DMS/pdf/PatientSafetyinHospitalsReportFINAL42905Post.pdf Accessed August 8, 2008).
16. Institute of Medicine. Antimicrobial drug resistance: Issues and options. Workshop report. Washington: National Academy Press; 1998.
17. Anderson DJ, Kirkland KB, Kaye KS, et al. Underresourced hospital infection control and prevention programs: Penny wise, pound foolish? Infect Control Hosp Epidemiol. 2007;28:767-773.
18. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175-1184.
19. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis. 2003;36:53-59. (Pubitemid 36099097)
20. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York hospitals. Emerg Infect Dis. 1999;5:9-17. (Pubitemid 29124770)
21. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592-598. (Pubitemid 36259564)
22. DiazGranados CA, Zimmer SM, Klein M, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin susceptible enterococcal bloodstream infections: A meta-analysis. Clin Infect Dis. 2005;41:327-333. (Pubitemid 41022109)
23. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect Control Hosp Epidemiol. 2003;24:690-698. (Pubitemid 37221342)
24. Roughmann M, Bradham D, South B, et al. The clinical and economic impact of antimicrobial drug resistance on nosocomial bloodstream infections. Infect Control Hosp Epidemiol. 2000; 21:97.
25. Song X, Srinivasan A, Blaut D, et al. Effect of nosocomial VRE bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol. 2003;24:251-256. (Pubitemid 36538136)
26. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(suppl 2):S82YS89.
27. Cosgrove SE, Kaye KS, Eliopoulous GM, et al. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med. 2002;162:185-190. (Pubitemid 34098188)
28. Apisarnthanarak A, Pinitchai U, Thongphubeth K, et al. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: A 3-year study. Clin Infect Dis. 2008;47:760-767.
29. Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium difficileYassociated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497-504. (Pubitemid 351263485)
30. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699-706. (Pubitemid 37221343)
31. White AC, Atmar RL, Wilson J. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25:230.
32. Fishman N. Antimicrobial stewardship. Am J Med. 2006;119:S53YS61.
33. LaRocco A. Concurrent antibiotic review programsVa role for infectious disease specialists at small community hospitals. Clin Infect Dis. 2003;37:742-743.
34. Ruttimann S, Keck B, Harmeier C, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis. 2004;38:348-356. (Pubitemid 38200110)
35. Standiford HC. Abstract #666. Antimicrobial stewardship: The cost of discontinuing a program. Presented at the Fifth Decennial International Conference on Healthcare-Associated Infections, Atlanta, GA, March 18-22, 2010.
36. Gentry CA, Greenfield RA, Slater LN, et al. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57:268-274. (Pubitemid 30112341)
37. Singh N, Rogers P, Atwood CW et al. Short course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med. 2000;162:505-511.
38. Apisarnthanarak A, Danchaivijitr S, Khawcharoenporn T, et al. Effectiveness of education and an antibiotic control program in a tertiary care hospital in Thailand. Clin Infect Dis. 2006;42:768-775. (Pubitemid 43363930)
39. Lipworth AD, Hyle EP, Fishman N. Limiting the emergence of extended spectrum beta-lactamaseYproducing Enterobacteriaceae: Influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol. 2006;27:279-286.
40. Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect. 2009;15:427-434.
41. Valiquette L, Cossette B, Garant MP, et al. Impact in the reduction in the use of high risk antibiotics in the course of an epidemic of Clostridium difficile associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45:S112YS121.
42. Johannsson B, Beekmann SE, Srinivasan A, et al. Improving antimicrobial stewardship: The evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol. 2011;32(4):367-374.
43. Bhavnani EM, Ambrose PG. Optimizing antimicrobial use and combating bacterial resistance: Benchmarking and beyond. In: Owens R, Ambrose PG, Nightingale CH, eds. Antibiotic Optimization: Concepts and Strategies in Clinical Practice. New York, NY: Dekker Press; 2005:181-188.
44. McQuillen DP, Petrak RM, Wasserman RB, et al. The value of infectious diseases specialists: Non-patient care activities. Clin Infect Dis. 2008;47:1051-1063.
45. Sunenshine RH, Liedtke LA, Jernigan DB, et al. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis. 2004;38:934-938. (Pubitemid 38457199)
46. Briceland LL, Nightingale CH, Quintiliani RQ, et al. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med. 1988;148:2019-2022.
47. Jenkins TC, Sabel AL, Sarcone EE, et al. Skin and soft tissue infections requiring hospitalization at an academic medical center: Opportunities for antibiotic stewardship. Clin Infect Dis. 2010;51:895-903.
48. Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med. 2006;34:2069-2074. (Pubitemid 44305607)
49. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109-1115. (Pubitemid 32554320)
50. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505-511. (Pubitemid 30647191)
51. Chastre J, Wolff M, Fagon JY. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA. 2003;290:2588-2598.
52. Mermel LA, Allon M, Bouzo E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the IDSA. Clin Infect Dis. 2009;49:1-45.
53. Willemsen I, van den Broek R, Bijsterveldt P, et al. A standardized protocol for perioperative antibiotic prophylaxis is associated with improvement of timing and reduction of costs. J Hosp Infect. 2007;67:156-160. (Pubitemid 47553539)
54. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy. 1997;17:271-276. (Pubitemid 27133352)
55. Li JZ, Willke RJ, Rittenhouse BE, et al. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: Results from a randomized clinical trial. Surg Infect (Larchmt). 2003;4:57-70. (Pubitemid 36546749)
56. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from iv vancomycin to po linezolid for the management of methicillin resistant Staphylococcus species. Clin Ther. 2003;25:3173-3189. (Pubitemid 38096154)
57. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655
58. Roberts GW, Farmer CJ, Cheney PC, et al. Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting. J Am Med Inform Assoc. 2010;17:308-312.
59. Lodise TP, Lomaestro B, Drusano GL. Pipericillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended infusion dosing strategy. Clin Infect Dis. 2007;44: 357-363. (Pubitemid 46147617)
60. Roberts JA, Kirkpatrick CMJ, Roberts M, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus vs continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142-150.
61. Bauer KA, West JE, Balada-Llasat JM, et al. An antibiotic stewardship program's impact with rapid polymerase chain reaction methicillin-resistant Staphylococcus aureus blood culture test in patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2010;51:1074-1080.
62. Forrest GN, Roghmann MC, Toombs LS, et al. Peptic nucleic acid fluorescent in situ hybridization for hospital acquired Enterococcal bacteremia: Delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother. 2008;52:3558-3563.
63. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program from antibiotics and other antiinfective agents. N Engl J Med. 1998;338:232-238. (Pubitemid 28047578)
64. Glowacki RC, Schwartz DN, Itokazu GS, et al. Antibiotic combinations with redundant antimicrobial spectra: Clinical epidemiology and pilot intervention of computer assisted surveillance. Clin Infect Dis. 2003;37:59-64. (Pubitemid 36836645)
65. Larsen RA, Evans RS, Burke JP, et al. Improved perioperative antibiotic use and reduced surgical wound infections through use of computer decision analysis. Infect Control Hosp Epidemiol. 1989;10:316-320.
66. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients; an update from LDS Hospital, Salt Lake City. Clin Infect Dis. 2001;33(suppl 2):S78YS83.
67. Sengstock DM, Thyagarajan R, Apara J, et al. Multidrug-resistant Acinetobacter baumannii: An emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis. 2010;50:1611-1616.
68. Van Schooneveld TV, Miller H, Wakins K, et al. A survey of antimicrobial stewardship practices in Nebraska long term care facilities. Abstract 577, SHEA, Dallas, TX. April 3, 2011.